Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.61 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415408 | 1.00 | PTGS2 (0.61) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7352630 | 0.98 | PTGS2 (0.59) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| SCHEMBL8658514 | 0.96 | PTGS2 (0.62) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| SCHEMBL2447766 | 0.93 | PTGS2 (0.64) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| SCHEMBL4198455 | 0.91 | PTGS2 (0.62) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| SCHEMBL7265178 | 0.85 | PTGS2 (0.50) | PTGS2RAB9AKDM4EALDH1A1MAOA | |
| SCHEMBL4884912 | 0.84 | PTGS2 (0.53) | PTGS2ACLYPTGS1MAOALOX | |
| SCHEMBL207671 | 0.84 | PTGS2 (0.44) | PTGS2ACLYRAB9AKDM4EALDH1A1 | |
| SCHEMBL8770199 | 0.84 | PTGS2 (0.53) | PTGS2ACLYRAB9APTGS1KMT2A | |
| SCHEMBL6904881 | 0.84 | PTGS2 (0.68) | PTGS2RAB9AKDM4EALDH1A1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006002088-A2 | AMINO-QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-01-05 | — | — | WO | claimed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003031398-A1 | 4'-METHANESULFONYL-BIPHENYL DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | disclosed |
| EP-0977756-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2000-02-09 | — | — | EP | disclosed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998049166-A1 | PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0794942-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016934-A1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885ACLY 3410/4885RAB9A 3160/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885ACLY 3410/4885RAB9A 3160/4885 |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885ACLY 3157/4885RAB9A 2030/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | PTGS2 2466/4885ACLY 3032/4885RAB9A 2161/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | PTGS2 24/4885ACLY 2953/4885RAB9A 4046/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | PTGS2 24/4885ACLY 2953/4885RAB9A 4046/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885ACLY 3410/4885RAB9A 3160/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885ACLY 3410/4885RAB9A 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.